Back to Search
KATHERINE MERKLE, DO
DO
Neuromusculoskeletal Medicine & OMM Physician
NPI: 1134415292IndividualAccepts Medicare
Specialties, Licenses & Credentials
Neuromusculoskeletal Medicine & OMM
Code: 204D00000X
DO176533(OR)
CMS Specialties
PrimaryUNDEFINED PHYSICIAN TYPE (SPECIFY)
Additional
FAMILY PRACTICEOSTEOPATHIC MANIPULATIVE MEDICINE
Education
OTHER
Class of 2011
Research & Publications (20)
ERP responses differentiate inverted but not upright face processing in adults with ASD.
PMID 19454620·Soc Cogn Affect Neurosci·2012
8-other
Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia.
PMID 19652068·J Clin Oncol·2009
3-trial
An investigation of the relationship between fMRI and ERP source localized measurements of brain activity during face processing.
PMID 19322649·Brain Topogr·2009
4-observational
Brief report: face configuration accuracy and processing speed among adults with high-functioning autism spectrum disorders.
PMID 18751880·J Autism Dev Disord·2009
8-other
A phase I study of bendamustine hydrochloride administered day 1+2 every 3 weeks in patients with solid tumours.
PMID 17486132·Br J Cancer·2007
3-trial
A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors.
PMID 17414628·Anticancer Drugs·2007
3-trial
Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO).
PMID 16402269·J Cancer Res Clin Oncol·2006
3-trial
Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy.
PMID 16292542·J Cancer Res Clin Oncol·2006
3-trial
Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC.
PMID 16096436·Anticancer Drugs·2005
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via 534 NW Pleasant View Way #100 · 2 locations total
- Address
- 534 PLEASANT VIEW WAY NW STE 100
ALBANY, OR 97321 - Phone
- (541) 812-5656
Quick Facts
- NPI
- 1134415292
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 2
- Years in Practice
- 15
- Publications
- 20
Are you this provider?
Claim Your Profile